Wave Life Sciences Ltd.
For the period ended Jan 12, 2026. Filed Jan 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jan 12, 2026 · Filed Jan 12, 2026
Use the contents to explore the available documents and sections.
WVE$3.37+4.5%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Additional clinical programs
Additional clinical programs
| • | WVE-N531 is an investigational exon skipping oligonucleotide being developed as a disease modifying treatment for boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. Wave remains on track to file a New Drug Application (NDA) in 2026 to support accelerated approval of WVE-N531 with monthly dosing. |
| • | WVE-003 is a first-in-class, allele-selective investigational oligonucleotide for the treatment of Huntington’s disease (HD). Wave has prepared an Investigational New Drug (IND) application for a potentially registrational Phase 2/3 study of WVE-003 and would plan to submit it in conjunction with a prospective strategic partner. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.